THE STUDY
Written english is okay but they did a ton of bullets that should be changed GENERAL COMMENTS
Overall comments: This is a systematic review discussing the SGTL2 receptor inhibitors used as combination therapy for treatment of type 2 diabetes. While this is an important topic as we need to know what is the best 2nd and 3rd line agent for type 2 diabetes, the article is limited in the lack of trials to include in this systematic review which make it tough to draw many conclusions regarding safety outcomes. In addition, only one of the studies is an active comparator while the rest are placebo controlled trials making the data less useful since we can't determine the comparisons between adding januvia versus an SGLT2 inhibitor for instance based on the data available. However, it does provide information on the general efficacy of SGLT2 inhibitors when used as combination therapy.
I mention a few major issues to address in revisions: 1) The introduction needs to address why this topic needed a systematic review. i.e. Few people know about the potential benefits or harms of SGTL2 inhibitors used as dual or triple combination therapy for type 2 diabetes; therefore, we decided to conduct as systematic review of SGTL2 inhibitors to assess the efficacy and safety of these agents used as combination therapy for adults with type 2 diabetes. Would add safety not just efficacy into all statements where you say you are assessing efficacy since you do also assess safety in your results.
2) The appendix table is okay but is so big and long that it does not provide a great summary of the articles within one viewing segment. I would recommend another summary table showing key aspects of the study so that all 5 articles can be viewed on one page listing in columns: N of participants, dose of drug in each arm and names of drugs in each arm can be listed as rows under each study, mean baseline a1c, mean age, gender, key inclusion/exclusion criteria, country of study, study quality, and change in a1c between groups (which can be calculated) and whether statistically significant differences between groups or not.
3) The discussion talks about the lack of long term data on safety and long term outcomes but does not mention the potential safety concerns of cancer, liver toxicity, and nephropathy. These were brought up in the FDA review of the drug and was why it was not yet FDA approved. I think it is reasonable to mention these issues to the reader and note that we need further studies specifically in these areas to address potential concerns of specific adverse effects. 4) I found the article results difficult to follow since there was no range in mean differences between groups. This could probably be helped by either putting that in the text or adding the summary table to the article as discussed in #2.
Minor issues: 1) Abstract background: consider adding at the end of the sentence ", and little is known regarding their efficacy and safety when used as dual or triple therapy for type 2 diabetes." This will help make it more clear to the reader why a systematic review needs to be conducted.
2) Abstract objective: consider adding "and safety" after effectiveness. May want to change effectiveness to efficacy since data are all from RCTs which are mainly efficacy trials not effectiveness trials done in the "real world".
3) Abstract Inclusion criteria: consider adding randomized before the word trials. 4) Abstract Results: Seems like you could put the range in between group differences for a1c and weight loss for the placebo controlled trials here. Also, trial quality appeared good does not sound scientific. You used a validated instrument to assess risk of bias-why not provide the quantitative results of that assessment in results. 5) Globally, I have never seen an article use so much bulleting before. One problem with bulleting is you feel a bit like you are reading an outline in some parts as opposed to a written article. Please fix that throughout unless the editor states differently. I would write it as a sentence with commas wherever this occurred. 6) I also found it hard to follow the headers since I am so used to articles being laid out in specific ways. (i.e. background, methods, results, and discussion). Usually, I only see subheadings under methods and results. I thought the subheadings in the background should be removed (i.e. subheading decision problem and review objectivescan keep text under subheadings just do not need the subheadings in my opinion -I found it confusing), and under methods need to make less subheadings -could divide into 3 sections: data sources and selection (include search strategy, inclusion/exclusion criteria here), data extraction and quality assessment, and data synthesis and analysis. 7) Would add rationale for systemative review as mentioned under major issues above prior to subheading listed as review objectives. 8) Would consider removing the sentence under decision problem that states we start from the position that the first line drug in type 2 diabetes is metfromin… Although I agree that these meds are unlikely to replace metformin, you do not need the sentence since will state rationale for why you are looking at it in combination therapy. You could add a sentence earlier instead when talking about rationale for not looking at it in monotherapy by stating that a recent systematic review has already evaluated the class as monotherapy. 9) Above participants on page 3, delete the two sentences above participants which discuss outcomes and looking at trials against placebo since this should be and is under methods already. Redundent and does not need to be here. 10) Would start methods before study participants and all the following information should be put without bullets under one of the three headings mentioned above. 11) Would remove all times when you state "if data permitted". You are just describing methods here. In results, you can state that there were no data to answer a specific question. 12) In methods when you describe looking at subgroups, would consider removing the categories of duration. Not needed really. Just use the statement that you already have regarding exploring duration of diabetes. 13) Report methods for synthesis of evidence of clinical effectiveness. I would move this sentence to right above your discussion of data synthesis and add the words "to be described in detail below". 14) Study selection: would add the words inclusion/exclusion before the word criteria for clarity. 15) I could not tell if the quality assessment was done independently by 2 reviewers. The word verified should be changed if it was done independently as verified makes me think someone only looked over someone's else's answers in which case it would be a serial not an independent review. 16) Usually the Figure 1 has two boxes above the one listed there. One box shows all sources of data and N of titles reviewed (i.e. medline N=12000, handsearch N=29, embase N=13000 with an N excluded between title and abstract review. A second box listing N abstracts reviews would come above N full articles reviewed with an arrow to the side listing N of exclusions. Usually there are some reasons for exclusion listed between abstract and full article review 21) It was not clear from the article that dapagliflozin reduces SBP based on 2 articles. In discussion, could say that it may also reduce SBP but need more data to further substantiate this or please make more evident why you think this is true. I did not feel that two RCTs with small differences in one of them was sufficient to say with certainty and unclear from results if the -2.7 was statistically significant. 22) In discussion, you list SGLT2 inhibitors under nine classes. Are these available for use in Canada? If so, keep here. If not, may want to point out that the other 8 classes are available for use and that this class is not yet approved for use in all countries. 23) Limitationsyou state wilder noted one case of renail failure. Seems like that should also be listed under adverse events section under results. 24) Statement about wilder matching by demographics but could be biased by differences in prior med use seemed a bit strange. If this was an RCT, then shouldn't the background meds have been similar between groups? Was it not? 25) Usually I see ceiling of effectiveness written as ceiling effect but that is in the US. If the Canadian terms are different, then leave as is. If not, then would change to ceiling effect. 26) In discussion, you state that UTIs were only mild infections not requiring treatment. May be worth adding a statement afterward that we need more studies with more people to have sufficient power to determine if there were differences in more serious UTIs requiring treatment. 27) In conclusions, you state that SGLT2 inhibitors appear safe as much as can be assessed via short term trials. I would probably take the safe part out hereyou could comment on the hypoglycemia effect if you want. You could state that they are effective at reducing a1c and weight. I would add a sentence stating that we can not be sure of its impact on long term outcomes or safety until long term large studies are conducted assessing both long term outcomes and rare adverse events such as cancer, renal failure, and liver toxicity among others. 28) Abstract conclusionwould remove safe from the sentence and would state effective at reducing a1c and weight in short term RCTs.
REVIEWER

Jennifer Hirst
Research Officer Department of Primary Care Health Sciences University of Oxford United Kingdom REVIEW RETURNED 28-Feb-2012
THE STUDY
This systematic review aims to assess the clinical effectiveness of SGLT2 inhibitors in diabetes. In its current form the review is not answering the research questions, and needs substantial revisions to provide a robust answer to a clinically relevant question.
Presentation of results in the abstract is too brief and and needs to provide an answer to the research questions Text in search methods states that 344 hits were returned from searches whereas Figure 1 , the Flow chart only begins with 73 articles. Nowhere in the text is this discrepancy clarified.
A description of the statistical methods needs to be given.
On page 6 details of study participants are presented, with numbers in brackets, it needs to be made clear whether these numbers represent the range or confidence intervals.
References for all the included studies should be included in the reference list.
Written presentation: Page 6 -Lead in periods -wording in the last sentence is unclear: "Only in the Rosenstock..."
Page 8 Body Weight -the first sentence extends to 6 lines and needs breaking into at least 3 sentences.
Page 8 last sentence -not clear what the message is here.
Appendix. One of the studies in the table (Rosenstock) has no details of number of participants Appendix: pages 15 and 16 -Group 4 -10mg dapagliflozin -is this in combination with metformin? If not, then it does not meet the inclusion criteria.
RESULTS & CONCLUSIONS
The results of this systematic review have been presented in graphical format, with data points from all included studies plotted together. In this format it is difficult to interpret the data, though the authors have attempted to do this through narrative and overall statements. The authors state that a meta-analysis was not conducted because of the small number and heterogeneity of the trials. As 5 trials have been included in the review, and each of these report outcomes which can be compared, a meta-analysis could be conducted. The authors throughout the paper make summary statements about the results, however the method of analysis used by the investigators is not appropriate to draw these conclusions. A meta-analysis should be conducted and would substantially improve the paper.
A table summarising the study characteristics of included studies is needed in the results section. Suggest to include details of intervention & comparator medications, numbers of participants in each arm, dose and length of study.
Advice is to re-conduct the data analysis using meta-analysis, however the following comments on the current analysis method and data interpretation are given:
The curved line connecting the points on the graphs implies that the trend has been observed. As this is not the case, a straight line or preferably a dotted line would be more appropriate. In addition, confidence intervals should be provided on the graphs, with data points being slightly offset so confidence intervals can be seen.
Results -1st paragraph -in the text report SGLT2 inhibitors to lower HbA1c by between -0.52 and -0.78%, but Figure 2 shows this to be between -0.37 and -0.78% -2nd paragraph -"no difference ... between dapagliflozin and glipizide" -Figure 2 appears to show a comparison of 2.5mg and 5mg. It is misleading to present data from an arm of the trial without dapagliflozin in this graph.
There is no discussion of Figure 3 or Figure 5 Body weight -median weight reduction of -2.33kg presented with confidence intervals. Is this mean rather than median? How was this calculation perfomed and which statistical package was used to get to this value? This value should be obtained using meta-analysis.
Significant reductions in weight, blood pressure and FPG reported without supporting statistics (means and confidence intervals).
Hypoglycaemic -"a small but not significantly significant increase in ..... hypoglycaemia across 3 of the 4 studies" -The way the data is presented makes it difficult to judge whether hypoglycaemia is an issue. A meta-analysis of this data is needed to clarify this.
Discussion
Page 11 -3rd paragraph. -"optimum dosage ...between 10-20mg"of your 5 trials, there was only 1 trial which used a dose of over 10mg, and this was the smallest of the included trials with a maximum of 23 patients in each arm. No confidence intervals are presented, it is therefore not possible to say whether the observed difference at 20mg is significantly different from that at 10mg. There is insufficient evidence presented to conclude that an optimum dosage of 10-20mg.
GENERAL COMMENTS
The presentation of the results in this review needs to be revised. This could be achieved by conducting a meta-analysis. Data could then be presented in subgroups of dose. A summary statistic estimate need not be presented particularly if heterogeneity is large, but should be considered. The authors are strongly urged to conduct a meta-analysis on their data.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 Written english is okay bit they did a ton of bullets that should be changed. Again, mentioned this in comments to authors.
Major comments
Overall comments: This is a systematic review discussing the SGTL2 receptor inhibitors used as combination therapy for treatment of type 2 diabetes. While this is an important topic as we need to know what is the best 2nd and 3rd line agent for type 2 diabetes, the article is limited in the lack of trials to include in this systematic review which make it tough to draw many conclusions regarding safety outcomes. In addition, only one of the studies is an active comparator while the rest are placebo controlled trials making the data less useful since we can't determine the comparisons between adding januvia versus an SGLT2 inhibitor for instance based on the data available.
Fair points, but we can only report what research there is. And it is not correct that only one trial had an active comparatorthere were two active comparators, glipizide in Nauck 2011 and sitagliptin in Rosenstock 2010.
However, it does provide information on the general efficacy of SGLT2 inhibitors when used as combination therapy.
1) The introduction needs to address why this topic needed a systematic review. i.e. Few people know about the potential benefits or harms of SGTL2 inhibitors used as dual or triple combination therapy for type 2 diabetes; therefore, we decided to conduct as systematic review of SGTL2 inhibitors to assess the efficacy and safety of these agents used as combination therapy for adults with type 2 diabetes. Would add safety not just efficacy into all statements where you say you are assessing efficacy since you do also assess safety in your results.
Section added at end of Introduction with similar message to referee's comments, and mentioning safety.
2) The appendix table is okay but is so big and long that it does not provide a great summary of the articles within one viewing segment. I would recommend another summary table
showing key aspects of the study so that all 5 articles can be viewed on one page listing in columns: N of participants, dose of drug in each arm and names of drugs in each arm can be listed as rows under each study, mean baseline a1c, mean age, gender, key inclusion/exclusion criteria, country of study, study quality, and change in a1c between groups (which can be calculated) and whether statistically significant differences between groups or not.
A summary table with all the variables suggested by the referee would be rather large, but we take the point that a summary table would be useful. We have inserted one which is not quite as extensive as he suggested.
3) The discussion talks about the lack of long term data on safety and long term outcomes but does not mention the potential safety concerns of cancer, liver toxicity, and nephropathy. These were brought up in the FDA review of the drug and was why it was not yet FDA approved. I think it is reasonable to mention these issues to the reader and note that we need further studies specifically in these areas to address potential concerns of specific adverse effects.
We have added a paragraph on the FDA review. 4) I found the article results difficult to follow since there was no range in mean differences between groups. This Table added could probably be helped by either putting that in the text or adding the summary table to the article as discussed in #2.
Minor issues 1) Abstract background: consider adding at the end of the sentence ", and little is known regarding their efficacy and safety when used as dual or triple therapy for type 2 diabetes." This will help make it more clear to the reader why a systematic review needs to be conducted.
We have added some text to the Objective in the Abstract to make it clear that our review is about the use of these drugs in dual or triple therapy.
Safety added.
3) Abstract Inclusion criteria: consider adding randomized before the word trials.
We have added "randomised controlled" 4) Abstract Results: Seems like you could put the range in between group differences for a1c and weight loss for the placebo controlled trials here. Also, trial quality appeared good does not sound scientific. You used a validated instrument to assess risk of bias-why not provide the quantitative results of that assessment in results.
Figures for
HbA1c changes added to Abstract. No change to "good quality" -it's a standard expression in systematic reviews.
Text on safety added to Abstract. 5) Globally, I have never seen an article use so much bulleting before. One problem with bulleting is you feel a bit like you are reading an outline in some parts as opposed to a written article. Please fix that throughout unless the editor states differently. I would write it as a sentence with commas wherever this occurred.
We don't think the use of bullets is excessive but will amend it if the editor wishes.
6) I also found it hard to follow the headers since I am so used to articles being laid out in specific ways. (i.e. background, methods, results, and discussion). Usually, I only see subheadings under methods and results. I thought the subheadings in the background should be removed (i.e. subheading decision problem and review
We have amended the structure slightly by having bolder headings for Introduction, Methods, Results, Discussion.
We have removed the subheading on objectives, and the sentence that followed it, from the Introduction, and have expanded the preceding paragraph. However we have kept the subheadings in Methods and Results.
objectivescan keep text under subheadings just do not need the subheadings in my opinion -I found it confusing), and under methods need to make less subheadings -could divide into 3 sections: data sources and selection (include search strategy, inclusion/exclusion criteria here), data extraction and quality assessment, and data synthesis and analysis. 7) Would add rationale for systemative review as mentioned under major issues above prior to subheading listed as review objectives.
Done 8) Would consider removing the sentence under decision problem that states we start from the position that the first line drug in type 2 diabetes is metfromin… Although I agree that these meds are unlikely to replace metformin, you do not need the sentence since will state rationale for why you are looking at it in combination therapy. You could add a sentence earlier instead when talking about rationale for not looking at it in monotherapy by stating that a recent systematic review has already evaluated the class as monotherapy.
Paragraph removedhaving expanded what is now the last paragraph of the Introduction, we no longer need the "Decision problem" section.
Sentence added. 9) Above participants on page 3, delete the two sentences above participants which discuss outcomes and looking at trials against placebo since this should be and is under methods already. Redundent and does not need to be here.
We have removed the sentence on outcomes, since those appear in the Methods section. However since Questions 1 and 2 focus on active comparators, we think it is worth retaining the sentence on placebo trials. We have reduced the length of this section by amalgamating questions 1 and 2. 10) Would start methods before study participants and all the following information should be put without bullets under one of the three headings mentioned above. Fair point. Text added to clarify.
21) It was not clear from the article that dapagliflozin reduces SBP based on 2 articles. In discussion, could say that it may also reduce SBP but need more data to further substantiate this or please make more evident why you think this is true. I did not feel that two RCTs with small differences in one of them was sufficient to say with certainty and unclear from results if the -2.7 was statistically significant.
All four dapagliflozin trials reported SBP reductions. Safe bit removed and paragraph on FDA review added.
28) Abstract conclusionwould remove safe from the sentence and would state effective at reducing a1c and weight in short term RCTs.
Done.
Reviewer 2 Jennifer Hirst Presentation of results in the abstract is too brief and and needs to provide an answer to the research questions Abstract is already close to word limit.
Text in search methods states that 344 hits were returned from searches whereas Figure 1 , the Flow chart only begins with 73 articles. Nowhere in the text is this discrepancy clarified.
Figure 1 revised to clarify this
None used.
Clarified by addition of "range"
Done
Written presentation: Page 6 -Lead in periods -wording in the last Revised sentence is unclear: "Only in the Rosenstock..."
Revised
That weight loss in trials may be due to being in the trial not due to the drugs.
Appendix. One of the studies in the table (Rosenstock) has no details of number of participants
The total number is given.
Appendix: pages 15 and 16 -Group 4 -10mg dapagliflozin -is this in combination with metformin? If not, then it does not meet the inclusion criteria.
Yes is in combination with metforminadded to box.
The results of this systematic review have been presented in graphical format, with data points from all included studies plotted together.
In this format it is difficult to interpret the data, though the authors have attempted to do this through narrative and overall statements. The authors state that a metaanalysis was not conducted because of the small number and heterogeneity of the trials. As 5 trials have been included in the review, and each of these report outcomes which can be compared, a metaanalysis could be conducted. The authors throughout the paper make summary statements about the results, however the method of analysis used by the investigators is not appropriate to draw these conclusions. A meta-analysis should be conducted and would substantially improve the paper.
A meta-analysis would have been entirely inappropriate because of the heterogeneity of the studies.
Noa meta-analysis should not be done. You can't combine a study of triple therapy with others of dual, or one of canaglifozin with some of dapagliflozin, or studies with different comparators.
A table summarising the study characteristics of included studies is needed in the results section. Suggest to include details of intervention & comparator medications, numbers of participants in each arm, dose and length of study. Table added with the arms of most interest.
The curved line connecting the points on the graphs implies that the trend has been observed. As this is not the case, a straight line or preferably a dotted line would be more appropriate. In addition, Lines removed.
confidence intervals should be provided on the graphs, with data points being slightly offset so confidence intervals can be seen.
Results -1st paragraph -in the text report SGLT2 inhibitors to lower HbA1c by between -0.52 and -0.78%, but Figure  2 shows this to be between -0.37 and -0.78%
Corrected.
-2nd paragraph -"no difference ... between dapagliflozin and glipizide" -Figure 2 appears to show a comparison of 2.5mg and 5mg. It is misleading to present data from an arm of the trial without dapagliflozin in this graph.
Accepted, and glipizide cross removed
There is no discussion of Figure 3 Body weight -median weight reduction of -2.33kg presented with confidence intervals. Is this mean rather than median? How was this calculation perfomed and which statistical package was used to get to this value? This value should be obtained using meta-analysis.
Figures were as calculated in original studies.
No meta-analysis should be done.
No change
Page 11 -3rd paragraph. -"optimum dosage ...between 10-20mg" -of your 5 trials, there was only 1 trial which used a dose of over 10mg, and this was the smallest of the included trials with a maximum of 23 patients in each arm. No confidence intervals are presented, it is therefore not possible to say whether the observed difference at 20mg is significantly different from that at 10mg. There is insufficient evidence presented to conclude that an optimum Fair point, and paragraph replaced with new one. dosage of 10-20mg.
The presentation of the results in this review needs to be revised. This could be achieved by conducting a metaanalysis. Data could then be presented in subgroups of dose. A summary statistic estimate need not be presented particularly if heterogeneity is large, but should be considered. The authors are strongly urged to conduct a meta-analysis of their data.
We remain convinced that a meta-analysis would not be appropriate. 
GENERAL COMMENTS Major comments
The authors have chosen to present the data reported in the included trials as graphs plotted in Excel. Despite the comprehensive reporting of confidence intervals in the included trials (for both HbA1c and body weight), the authors have not included these confidence intervals for HbA1c in their graphs or in the text. This means that a reader is unable to make any judgement about the statistical significance of the results presented in this paper. A systematic review can influence healthcare decisions and needs to provide a comprehensive and unbiased summary of research on a topic. It therefore needs to have the same rigour that is expected of all research, which includes adequate reporting of statistical data.
In order to answer the research question in this paper and draw conclusions from this work the authors need to report confidence intervals. I would not expect the editor to publish this paper unless confidence intervals are presented in the text, abstract and graphs. It is possible that another statistical package may be easier than Excel for achieving this in the graphs.
The authors have stated that a meta-analysis was not appropriate for combining data from the included trials because of heterogeneity. Are the authors referring here to clinical or statistical heterogeneity? And could they explain their rationale behind this? On examination of the included trials it is not clear why three of the trials, Bailey, Strojek and Wilding cannot be combined. All three of the trials compare dapagliflozin added to a background medication versus the background medication alone. A very quick meta-analysis in RevMan on change in HbA1c from these 3 trials gives a significant reduction in HbA1c of 0.62% (p<0.01) by 10mg dapagliflozin compared with background therapy, with an I-squared of 0% (indicating that there is no statistical heterogeneity). There are many examples of published meta-analyses in which trials of medications added to different background therapies have been combined in a similar way (Lasserson, Diabetologia. 2009 Oct; 52(10):1990 -2000 Hirst, Diabetes Care. 2012 Feb; 35(2):446-54; Sherifali, Diabetes Care. 2010 Aug; 33(8):1859-64) . In addition, the research question prompting this systematic review was to assess the efficacy of SGLT2 inhibitors when added-on to another glucose-lowering medication, meta-analysing results from these 3 trials would provide a quantitative answer to this question. Including such an analysis in this paper would significantly improve it and add weight to the conclusions; I strongly encourage the authors to re-consider this.
The sentence in the discussion (page 10) needs to be removed: "The present evidence suggests that the optimum dose of dapagliflozin may be 10mg once daily, since there appears to be little additional benefit from increasing the dose to 20mg." As doseeffects were not examined or discussed in the individual trials, the authors would first need to use an appropriate statistical method to examine the effect of a dose increase on each of their outcomes if they wish to report this. If they are not planning to analyse the data they need to remove this sentence.
Also page 12. Likewise the sentence "They come to similar conclusions about a ceiling of effectiveness for dapagliflozin doses of approximately 10-20mg/d" needs to be removed -these conclusions cannot be drawn without appropriate analysis.
Other comments:
Abstract: "Dapagliflozin reduced HbA1c, by 0.54% to 0.7%". -Correct this to: Dapagliflozin reduced HbA1c, by between 0.37% and 0.78% Figure 1 -flow chart needs modifying: "Initial search….. dapagliflozin and canagliflozin"
Addition of Table 1 into the paper giving details of the included trials is an improvement but the table would benefit from a column with numbers of participants in each arm. The Rosenstock trial needs to specify that metformin was used as background therapy in both arms and confidence intervals need to be added.
The reference provided for the Rosenstock paper is a conference abstract, but there is a publication of this trial published on-line in Diabetes Care: http://care.diabetesjournals.org/content/early/2012/04/05/dc11-1926.full.pdf this paper should be cited instead of the abstract as in press. Additional data are available including confidence intervals for the change in HbA1c and body weight. The text in the paper referring to limitations of reporting in the conference abstract can be amended.
Page 8 -Weight:
The authors report "….a median weight reduction of -2.33kg (95% CI: -1.19 to -4.50)", please specify which trial this data was taken from, which drug was used and at which dose, and whether this was absolute change or change compared to placebo?
"….greatest reduction reported by Wilding (2009), of -4.50 kg with 10mg dapagliflozin compared to a reduction of +1.9kg on placebo." Please add confidence intervals to these numbers so the readers can see that this reduction is significant.
The lowest reduction was reported to be: "….by Strojek, of -0.84kg with 5mg dapagliflozin." This is not correct as the lowest reduction was reported by Strojek for 2.5 mg dapagliflozin and was a nonsignificant reduction of -0.46 (95%CI -1.08 to 0.15). This needs to be corrected in the text.
"….however some of these effects were probably as a result of the trial effect, rather than a direct effect of the comparator drugs."possibly would be a more appropriate word than probably here, the term "trial effect" needs explaining to the reader. In addition, as the so-called "trial effect" would apply equally to both arms of the trial, then mentioning this may suggest that it is only an effect observed in the placebo arm.
"The abstract for Rosenstock (2010) suggests that for weight change, there was no difference between canagliflozin 300mg once daily and twice daily." -This sentence does not tell the reader much about the trial which found that all doses of canagliflozin significantly reduced weight compared with placebo. More details should be included on the findings of this trial.
As with HbA1c reduction, if the authors conducted a meta-analysis on weight reduction for the 3 trials, Wilding, Bailey & Strojek, they would be able to present much stronger evidence on the benefits of these drugs.
Systolic blood pressure, fasting plasma glucose and adverse events: Where significant results are reported, please give either confidence intervals or p-values for each of the trials to show significance.
Page 10 -Discussion
Spelling -line 33, last work should read shown
Poor grammar -line 43: "…expected to be less."
VERSION 2 -AUTHOR RESPONSE
Reviewer: Shari Bolen MD > > I could not view the references -refer to my first review comments. If I thought up to date before i assume that would be no different now.
No response required > Interesting article. The authors appropriately addressed the comments. The summary table really helps the reader.
Thanks.
The only thing which may still be useful to a reader is a comment in the table about whether the differences are statistically significant. Could be a footnote to the summary table or could include SE in figure or table for a1c.
Significance data added where available. Not all trials provided complete data.
> Reviewer: Jennifer Hirst > The authors have chosen to present the data reported in the included trials as graphs plotted in Excel. Despite the comprehensive reporting of confidence intervals in the included trials (for both HbA1c and body weight), the authors have not included these confidence intervals for HbA1c in their graphs or in the text. This means that a reader is unable to make any judgement about the statistical significance of the results presented in this paper. A systematic review can influence healthcare decisions and needs to provide a comprehensive and unbiased summary of research on a topic. It therefore needs to have the same rigour that is expected of all research, which includes adequate reporting of statistical data.
In order to answer the research question in this paper and draw conclusions from this work the authors need to report confidence intervals. I would not expect the editor to publish this paper unless confidence intervals are presented in the text, abstract and graphs. It is possible that another statistical package may be easier than CIs added in table 2 Excel for achieving this in the graphs.
> The authors have stated that a meta-analysis was not appropriate for combining data from the included trials because of heterogeneity. Are the authors referring here to clinical or statistical heterogeneity? And could they explain their rationale behind this?
The heterogeneity is clinical.
On examination of the included trials it is not clear why three of the trials, Bailey, Strojek and Wilding cannot be combined. All three of the trials compare dapagliflozin added to a background medication versus the background medication alone.
In Bailey, the comparison is versus placebo in patients on metformion alone. In Strojek, the comparison of interest is against glimepiride. In Wilding, patients are on insulin and metformin or pioglitazone. These are different clinically.
In addition, Wilidng is only for 12 weeks, and the others for 24. Lastly, Strojek gives the CI only for the difference from placebo and no measure of variance for individual groups, so a meta-analysis could only be done by inventing a SD. There are many examples of published metaanalyses in which trials of medications added to different background therapies have been combined in a similar way (Lasserson, Diabetologia. 2009 Oct; 52(10):1990 -2000 Hirst, Diabetes Care. 2012 Feb; 35 (2) It is easy to do meta-analyses, and perhaps too easy. In the three papers quoted, heterogeneity as measured by I 2 is often very high. For example, in the paper by Hirst et al, there are I
